Navigation Links
Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
Date:3/26/2013

28;higkeiten bei der Neupositionierung von Medikamenten", sagte Aris Persidis, Präsident von Biovista. "Wir glauben, dass diese Art von Kooperationen bezeichnend für Interessengruppen ist, die sich darum bemühen, auf neuartige Weisen Therapien zu entwickeln, die direkter ihre spezifischen Bedürfnisse ansprechen, und wir freuen uns auf die Zusammenarbeit mit DART Therapeutics."

Über Biovista

Biovista ist ein nicht börsennotiertes Biotechnologie-Unternehmen, das sich auf die Ermittlung neuer Anwendungsbereiche für bereits zugelassene Medikamente sowie die Erstellung von Profilen zu ihren Nebenwirkungen spezialisiert hat, die über das entsprechende Wirkprinzip ermittelt werden. Biovista entwickelt eine eigene Produktpipeline von Medikamenten für das ZNS, die Onkologie sowie Autoimmun- und seltene Krankheiten. Biovista arbeitet mit biopharmazeutischen Unternehmen an der Erweiterung von Indikationsbereichen und der Risikobereinigung ihrer Portfolios zusammen. Sie unterstützt zudem die FDA bei der Vorhersage von Nebenwirkungen und Interessengruppen von Patienten bei der Neupositionierung von Medikamenten. (http://www.biovista.com).

Über DART Therapeutics

DART Therapeutics Inc. aus Cambridge, Massachusetts, ist ein Biotechnologie-Unternehmen, da ein neues Modell für Medikamentenentwicklung auf seltene pädiatrische neuromuskuläre Krankheiten anwendet. Beim DART-Modell haben sich Patientenstiftungen und Biotechnologie-Industrie-Veteranen zusammengeschlossen, um Einfluss auf ein zentrales Problem bei seltenen Krankheiten zu nehmen: die rasche Therapie-Entwicklung. DART konzentriert sich auf DMD, eine tödliche neuromuskuläre Erkrankung, für die es keine wirksame Behandlung gibt. (http://www.dartrx.com).

Kontakte:
Biovista, Inc.
Aris Persidis
+1
'/>"/>

SOURCE Biovista, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... for cells and tissues  ("BioLife" or the "Company"), ... financial results will be released on Thursday, March 12, ... call and live webcast at 1:30 p.m. PT that ...
(Date:3/5/2015)...  Twelve patients today are preparing to participate in ... California Pacific Medical Center (CPMC), a Sutter Health affiliate. ... be the largest single-center kidney paired donation chain conducted ... the 44-year history of the CPMC Transplant Center. The ... altruistic donor who did not have a specific recipient ...
(Date:3/5/2015)... Paul, Minn. (PRWEB) March 05, 2015 ... in Pasadena this summer at the Annual Meeting of ... are starting to be released online now at ... been announced for the meeting, to be held August ... newly announced Special Sessions, Field Trips, Workshops, and committee ...
(Date:3/5/2015)... 2015 North Carolina-based life sciences ... Professor of Medicine, Mayo Clinic College of Medicine, ... Directors. , Entegrion’s Executive Chairman John ... have Dr. Noel, a distinguished physician and researcher ... Entegrion’s Board. His expertise in hematology and military ...
Breaking Biology Technology:BioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015 2Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 2Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 3Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 4American Phytopathological Society Announces Annual Meeting Daily Schedule 2Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2
... Oct. 31, 2011 Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... 30, 2011. For the third quarter of 2011, ... fully diluted share outstanding, compared to net income of $3.3 million, ... in 2010. For the nine months ended September 30, 2011, the ...
... (NYSE Amex: PIP ) announced today further ... SparVax™.  The new vaccine is being developed to provide ... emergency.  The Company completed its first cGMP manufacturing run ... ongoing and expected to be completed in December. ...
... Blood Pressure , aka Hypertension , is ... mostly ineffective.   Fortunately , Hypertensive patients ... methods that are both effective, inexpensive, and risk free. ... help reduce   Chronic Heart/Cardiovascular Disease patients,   ...
Cached Biology Technology:Neurocrine Biosciences Reports Third Quarter 2011 Results 2Neurocrine Biosciences Reports Third Quarter 2011 Results 3Neurocrine Biosciences Reports Third Quarter 2011 Results 4Neurocrine Biosciences Reports Third Quarter 2011 Results 5Neurocrine Biosciences Reports Third Quarter 2011 Results 6Neurocrine Biosciences Reports Third Quarter 2011 Results 7Neurocrine Biosciences Reports Third Quarter 2011 Results 8PharmAthene Progresses Second Generation rPA Anthrax Vaccine 2PharmAthene Progresses Second Generation rPA Anthrax Vaccine 3PharmAthene Progresses Second Generation rPA Anthrax Vaccine 4Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care 2
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... Hall E -   EyeLock Inc. , a market leader ... its EyeLock ID technology integrated in a 3D printed automobile ... Ridge National Laboratory (ORNL) at the 2015 North ... is being used to validate the driver and authorize the ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... An epidemic of the viral disease nephropathia epidemica (NE) ... caused by hotter summers, milder winters and increased seedcrop ... open access International Journal of Health Geographics ... of global warming. Dr Jan Clement from the ...
... there really plenty of fish in the sea? University ... first-ever estimate of total fish biomass in our oceans: ... unrecognized but significant role in mitigating climate change by ... to a study published in tomorrow,s edition of the ...
... and biochemistry from the University of Salamanca (Spain) and ... at the Public University of Navarre, has enhanced the ... of certain fungal and bacterial genes., In concrete, ... study of microorganisms with various levels of pregenomic information ...
Cached Biology News:Global warming linked to European viral epidemic 2UBC researcher gives first-ever estimate of worldwide fish biomass and impact on climate change 2Biologist enhances use of bioinformatic tools and achieves precision in genetic annotation 2Biologist enhances use of bioinformatic tools and achieves precision in genetic annotation 3
... & visualization software. See ... samples. Combine Sequest and ... confidence. Get more detailed ... your MS/MS experiments.14 day ...
... Clone/PAD: ZMD.467. Immunogen: Synthetic peptide ... the human rat mouse dog and ... for the human occludin protein. ... lysates). Reactivity with rat mouse ...
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Antibodies were affinity purified using epitopes specific to UBAP2L/NICE4 immobilized on solid support....
Biology Products: